MOLECULAR EXPRESS, INC — Department of Health and Human Services SBIR Phase I: NIAID
MOLECULAR EXPRESS, INC — SBIR Phase I award from Department of Health and Human Services.
Phase I SBIR feasibility signal
- Phase I awards fund proof-of-concept work. For capture teams, they mark early interest from Department of Health and Human Services in a technical approach.
- Watch for Phase II follow-ons from the same firm/topic family — that conversion path is where budgets and transition pressure rise.
- Obligated amount $599,596 is consistent with substantial Phase II-scale effort; compare to related awards from the same agency.
- Topic code NIAID links this award to a solicitation family — search the same topic stem for incumbents and recompete timing.
- Amount
- $599,596
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- Topic
- NIAID
- Solicitation
- PA20-260
- NAICS
- —
- Place of performance
- CA
- Period
- 2022-02-18 → 2024-01-31
Description
Project SummaryThe principal goal of this project is to develop a VesiVax®-based vaccine against Neisseria gonorrhoeae (Ng). The studies proposed in this SBIR Phase I application will be focused on co-formulating an newly identified surface-displayed outer membrane Ng protein, MtrE, with various immunostimulatory adjuvant molecules (IAMs) in the VesiVax® liposomal platform. We will characterize the immunogenicity of these VesiVax®-MtrE-IAM formulations in mice, and select for the best candidates to be further evaluated in a novel mouse upper reproductive tract Ng infection model. These studies will elucidate the immunological profile in a vaccine that will correlate with protective immunity against Ng.